Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Granules India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRANULES 532482

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

31
Market Live: Sensex sees a sharp surge, Nifty hits 10,800; banks, pharma soar

2018-06-22 moneycontrol
Market Check: Equity benchmarks are trading at the high points of the day, with the Nifty hitting 10,800-mark now. The Sensex is up over 100 points. Strong gains in financials, namely PSU banks, is aiding sentiment on D-Street. Sharp upmoves are visible in sectors such as pharma, FMCG, energy and infra names. Midcaps too have added to their gains, trading around quarter of a percent higher. Sun Pharma is leading the gainers chart on Sensex and Nifty, followed by Bajaj Finance and M&M, while Reliance, Wipro, and HPCL have lost the most.
BHRYY 500325 500228 RELIANCE IDBI HCTHY 512573 532714 531768 500470 GRANULES 532482 534816 RIGD 500135 532281 HDFCBANK 500378 BJJQY INFRATEL KEC RLNIY 500034 500116 AVANTI IBN ESSELPRO JSWSTEEL ICICIBANK BAJFINANCE TTST TATASTEEL TATLY HDB 532174 500180 JINDALSAW HCLTECH 534809 PCJEWELLER POLYMED

31
Market Live: Rangebound trade continues ahead of OPEC decision; ITC, HDFC support

2018-06-22 moneycontrol
Jindal Saw in focus: Pipe manufacturer Jindal Saw said it is currently not exporting large diameter pipes to the United States and the countervailing duty imposed by the US won't have any impact on company's business.
BHRYY 500325 500228 RELIANCE IDBI 533273 HCTHY 512573 532714 500470 GRANULES 532482 534816 RIGD 500135 532281 HDFCBANK 500378 BJJQY INFRATEL KEC RLNIY 500034 500116 AVANTI IBN ESSELPRO JSWSTEEL ICICIBANK OBZIY BAJFINANCE TTST OBEROIRLTY TATASTEEL TATLY HDB 532174 500180 JINDALSAW HCLTECH 534809 PCJEWELLER

20
Market Live: Sensex ranged; crude oil prices up over 1% as traders await OPEC decision

2018-06-22 moneycontrol
MTNL in Focus: MTNL share price rallied more than 8 percent after CNBC-TV18 reports quoting NewsRise that Department of Telecommunication may discuss the revival plan for BSNL and MTNL with the Prime Minister Office today.
BHRYY 500228 533273 HCTHY 512573 532714 500470 GRANULES 532482 534816 500135 532281 BJJQY INFRATEL KEC 500034 AVANTI IBN ESSELPRO JSWSTEEL ICICIBANK OBZIY BAJFINANCE TTST OBEROIRLTY TATASTEEL TATLY 532174 HCLTECH 534809 PCJEWELLER

20
Market Live: Nifty consolidates ahead of OPEC decision: RIL under pressure

2018-06-22 moneycontrol
Buzzing: HCL Technologies stock price gained nearly a percent after Finnish networking and telecommunications equipment company Nokia has signed a five-year deal with the firm for modernising its IT infrastructure and applications landscape.
500228 533273 HCTHY 512573 532714 500470 GRANULES 532482 500135 532281 BJJQY KEC 500034 AVANTI IBN ESSELPRO JSWSTEEL ICICIBANK OBZIY BAJFINANCE TTST OBEROIRLTY TATASTEEL TATLY 532174 HCLTECH 534809 PCJEWELLER

20
Market Live: Sensex, Nifty open mildly lower: Asia mixed ahead of OPEC meeting

2018-06-22 moneycontrol
Order Win: Consortium of Capacit'e Infraprojects, Tata Projects Limited and CITIC Construction has received letter of acceptance from Mumbai Housing and Area Development Board (a MHADA Unit) for total contract value of Rs 11,744.26 crore.
500228 533273 HCTHY 512573 532714 500470 GRANULES 532482 532281 BJJQY KEC 500034 AVANTI IBN JSWSTEEL ICICIBANK OBZIY BAJFINANCE TTST OBEROIRLTY TATASTEEL TATLY 532174 HCLTECH 534809 PCJEWELLER

0
Granules India Limited - Allotment of Securities

2018-06-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRANULES 532482

0
Indian pharma cos may soon find a way to the lucrative Chinese market

2018-06-19 moneycontrol
Indian pharma companies may finally find a way to mount the wall that prevented them from making the most of the lucrative market in China.
GRANULES 532482

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...